Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence study of generic bilastine 20 mg vs Bilaxten 20 mg in healthy Thai volunteers (fasting)
TCTR20250909008Phase 1Not yet recruiting
- Sponsor
- International Bio Service
- Start
- Nov 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of bilastine in allergic rhinitis (AR) and urticaria (2 arms), sponsored by International Bio Service. Primary endpoint: Bioequivalence of bilastine generic vs reference. Planned start Nov 2025; status: not yet recruiting.
02
Drugs
bilastine
03
Conditions
allergic rhinitis (AR)urticaria
Beyond the preview
Go deeper on TCTR20250909008.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on TCTR20250909008.